The FDA has posted an ongoing Class II recall of sildenafil citrate USP active pharmaceutical ingredient, supplied in 100 gram bags labelled for prescription compounding only, made by Shoolin Pharma Chem LLP, following good manufacturing practice deviations identified during an FDA inspection.
The distinction that matters is what is being recalled. This is bulk active ingredient destined for compounding pharmacies, not finished tablets from a licensed manufacturer - so no patient's ordinary prescription of branded or generic sildenafil is affected. Class II means the defect may cause temporary or medically reversible harm, and GMP deviations found on inspection mean the manufacturing process did not meet standards, rather than that a specific contaminant or potency failure was found in the product.
The practical relevance is to compounded preparations, which is where sildenafil turns up in paediatric pulmonary hypertension suspensions and in unlicensed combination products. If you prescribe or supply a compounded sildenafil preparation, ask the pharmacy about the ingredient source. The broader point is worth stating plainly to patients: sildenafil obtained outside the regulated supply chain - online, in combination 'performance' products, or compounded in unregistered facilities - carries exactly this class of risk, with none of the surveillance that generated this notice.
- Check the ingredient source with the pharmacy if you use compounded sildenafil preparations
- Reassure patients on licensed tablets that this recall does not affect them
- Take particular care with paediatric pulmonary hypertension suspensions, which are often compounded
- Warn patients against sildenafil sourced online or in unlabelled combination products
- Record the brand and supplier where a compounded preparation is used long term
Why it matters
Bulk-ingredient recalls reach patients through compounded preparations, where the prescriber usually has no idea who made the powder.
Don't overread it
This is a good manufacturing practice failure at an ingredient supplier, not a safety finding about sildenafil or about licensed finished products.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for urology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free